Floatz logo

(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE

Ovarian Neoplasm

Corcept TherapeuticsSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

78 Active assets in the Ovarian Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
GlaxoSmithKline
Phase 4BBB
gw786034
The Christie NHS Foundation Trust
Phase 2BB
Carboplatin
Eli Lilly and Company
Phase 3BB
tlk286
Telik
Phase 3BB
Docetaxel
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

(R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1,4,5,6,7,8-HEXAHYDRO-4AH-PYRAZOLO(3,4-G)ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE is also rated in:

Cushing syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
peritoneal neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →